Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Multicentre US trials for Healos bone graft:

This article was originally published in Clinica

Executive Summary

Swiss company Sulzer Medica has begun a US multicentre clinical trial of Orquest's Healos bone graft substitute used in combination with Sulzer's BAK interbody fusion device, following positive preliminary trial results. Healos, a mineralised collagen product, could eliminate the need to harvest the patient's own bone during spinal surgery, thus reducing hip pain, surgery time and hospital stay. The BAK device is produced by Winterthur-based Sulzer's subsidiary Sulzer Spine-Tech, which holds exclusive worldwide (excluding Japan) marketing rights and distribution rights for Healos. Mountain View, California-based Orquest CE-marked the bone graft last year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT072992

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel